08-05-2012

Affymetrix, Inc., and eBioscience, Inc. announced they have amended their existing definitive agreement dated November 29, 2011 under which Affymetrix will acquire eBioscience. Under the terms of the amended agreement, Affymetrix will acquire eBioscience for $315 million in cash subject to ...

more

17-02-2011

Composed of more than 4 billion nucleotides, a draft sequence of the Neandertal genome won the 2010 Newcomb Cleveland Prize of the American Association for the Advancement of Science (AAAS).The Association's oldest prize, now supported by Affymetrix, the Newcomb Cleveland Prize annually ...

more

17-03-2008

Roche NimbleGen Inc., a company of Roche Applied Science, and Affymetrix Inc. announced that they have expanded the terms of the license to a number of Affymetrix patents originally granted in October 2006. The expanded license now provides certain diagnostic rights for array-based DNA copy ...

more

15-01-2008

Affymetrix, Inc. and Illumina, Inc. announced that they have entered into a settlement agreement to resolve their patent litigation. Under the terms of the settlement, Illumina agreed, without admitting liability, to make a one-time payment to Affymetrix of $90 million. Affymetrix agreed to ...

more

11-09-2007

Affymetrix Inc. announced that Empire Genomics, LLC, has obtained a non-exclusive, worldwide license to a number of Affymetrix patents covering the manufacturing, use and sales of nucleic acid microarrays and related products and services for comparative genomic hybridization (CGH). The ...

more

11-07-2007

Affymetrix Inc. announced the launch of the European Cytogenetic Research Initiative, a collaboration between Affymetrix, the University of Nijmegen in the Netherlands, the University of Tuebingen in Germany and the NHS Regional Genetics Laboratory in Birmingham, U.K. The collaborators are ...

more

24-05-2007

Affymetrix Inc. officially opened its manufacturing facility in Singapore. The new state-of-the-art building is Affymetrix's first manufacturing facility outside of the United States of America, enabling the company to better serve and support its growing international business. "While ...

more

Partnership With Leading Scientists Aims to Accelerate Breakthroughs in More Than 10 Types of Cancers

19-04-2007

Affymetrix Inc. announced the launch of the Collaborations in Cancer Research Program, an alliance between Affymetrix and up to 30 leading European cancer researchers. As part of the program, Affymetrix will partially fund selected research projects that demonstrate clinical utility, enabling ...

more

Research Team to Use Affymetrix GeneChip(R) Technology to Develop Applications for Cancer and HIV/AIDS

26-01-2007

Affymetrix Inc. and Vanderbilt-Ingram Cancer Center announced that they have entered into a three-year translational research collaboration to analyze genomic information across a large number of patient samples. Under terms of the agreement, researchers at Vanderbilt-Ingram and Vanderbilt ...

more

21-12-2006

Affymetrix Inc. announced that it has appointed Kevin M. King to president of life sciences business and executive vice president, reporting to Stephen P.A. Fodor, Ph.D., chairman and CEO. King previously served as president and CEO of Thomson Healthcare, the $500 million healthcare and ...

more